Reviving old antibiotics with adjuvants that block bacterial transcription
This article was originally published in Start Up
Bacteria continue proving themselves immensely capable of resisting formerly effective antibiotics, and likewise capable of thwarting drugmakers’ efforts to create new types of compounds. The founders of BioVersys AG believe they can identify compounds uniquely able to block certain bacterial resistance factors; they aim to develop such molecules as adjuvants to be given in combination with existing antibiotics, to help restore their potency.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.